Clinical Trial

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

Study acronym: THYME
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of inebilizumab administered in pediatric participants with gMG, and to assess the safety and tolerability of inebilizumab administered in pediatric participants with gMG.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-05-16; most recent amendment 2026-07-08.
Status change: Not Yet Recruiting → Recruiting 2025-10-28
Trial Details
NCT Number NCT06987539
Lead Sponsor Amgen
Conditions Generalized Myasthenia Gravis
Enrollment 15 participants
Start Date 2026-08-31
Primary Completion 2030-03-13 (estimated)
Study Completion 2030-03-13 (estimated)
Updated on ClinicalTrials.gov 2026-07-09